188 related articles for article (PubMed ID: 32736531)
1. New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study.
Kim SH; Jhee JH; Choi HY; Lee SH; Shin SK; Lee SY; Yang DH; Yi JH; Han SW; Jo YI; Park HC
BMC Nephrol; 2020 Jul; 21(1):317. PubMed ID: 32736531
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial.
Kee YK; Han SY; Kang DH; Noh JW; Jeong KH; Kim GH; Kim YW; Kim BS
Yonsei Med J; 2021 Jan; 62(1):41-49. PubMed ID: 33381933
[TBL] [Abstract][Full Text] [Related]
3. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.
Wu IW; Hsu KH; Sun CY; Tsai CJ; Wu MS; Lee CC
Nephrol Dial Transplant; 2014 Sep; 29(9):1719-27. PubMed ID: 24714415
[TBL] [Abstract][Full Text] [Related]
4. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure.
Iida S; Kohno K; Yoshimura J; Ueda S; Usui M; Miyazaki H; Nishida H; Tamaki K; Okuda S
Clin Exp Nephrol; 2006 Dec; 10(4):262-7. PubMed ID: 17186330
[TBL] [Abstract][Full Text] [Related]
5. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
Yamaguchi J; Tanaka T; Inagi R
Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
[TBL] [Abstract][Full Text] [Related]
7. Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients.
Huang ST; Shu KH; Cheng CH; Wu MJ; Yu TM; Chuang YW; Chen CH
Transplant Proc; 2012 Apr; 44(3):621-4. PubMed ID: 22483453
[TBL] [Abstract][Full Text] [Related]
8. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
Liu WC; Tomino Y; Lu KC
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
[TBL] [Abstract][Full Text] [Related]
9. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
10. Review of the efficacy of AST-120 (KREMEZIN
Asai M; Kumakura S; Kikuchi M
Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
[TBL] [Abstract][Full Text] [Related]
11. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
12. The Difference in the Changes of Indoxyl Sulfate after Catheter Ablation among Atrial Fibrillation Patients with and without Kidney Dysfunction.
Koike H; Morita T; Tatebe J; Watanabe I; Shinohara M; Kinoshita T; Yuzawa H; Suzuki T; Fujino T; Ikeda T
Sci Rep; 2020 Jan; 10(1):513. PubMed ID: 31949282
[TBL] [Abstract][Full Text] [Related]
13. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
[TBL] [Abstract][Full Text] [Related]
14. Targeting protein-bound uremic toxins in chronic kidney disease.
Niwa T
Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
[TBL] [Abstract][Full Text] [Related]
15. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
[TBL] [Abstract][Full Text] [Related]
16. The relationship between serum indoxyl sulfate and the renal function after catheter ablation of atrial fibrillation in patients with mild renal dysfunction.
Koike H; Morita T; Tatebe J; Watanabe I; Koike M; Yao S; Shinohara M; Yuzawa H; Suzuki T; Fujino T; Ikeda T
Heart Vessels; 2019 Apr; 34(4):641-649. PubMed ID: 30406286
[TBL] [Abstract][Full Text] [Related]
17. Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort study.
Park HC; Cho A; Kim DH; Yun KS; Kim J; Lee EY; Jo SK; Lee SY; Han KH; Chang YK; Oh DJ; Lee YK
PLoS One; 2021; 16(6):e0252186. PubMed ID: 34097687
[TBL] [Abstract][Full Text] [Related]
18. [Serum indoxyl sulfate is a useful predictor for progression of chronic kidney disease].
Namba S; Okuda Y; Morimoto A; Kojima T; Morita T
Rinsho Byori; 2010 May; 58(5):448-53. PubMed ID: 20560454
[TBL] [Abstract][Full Text] [Related]
19. Uremic toxicity of indoxyl sulfate.
Niwa T
Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
[TBL] [Abstract][Full Text] [Related]
20. Indoxyl sulfate is a nephro-vascular toxin.
Niwa T
J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
